We have isolated and characterized three anti-recombinant human erythropoietin (rHuEPO) monoclonal antibodies (MoAbs) that recognize nonoverlapping epitopes on rHuEPO. Anti-EPO MoAb D11 neutralizes rHuEPO activity whereas MoAbs F12 and 9G8A do not. This suggests that D11 may bind to the rHuEPO active site. MoAbs F12 and D11 recognize conformation dependent epitopes whereas 9G8A does not. Immunoassays were developed for each mono-
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RYTHROPOIETIN (EPO) is a glycoprotein hormone
with a molecular weight of approximately 30,400.' EPO is produced primarily in the kidney and is the primary regulator of erythropoie~is.*-~ The human EPO gene has been cloned and recombinant material has been produced.'" Recombinant human EPO (rHuEPO) is used therapeutically to reverse the anemia associated with kidney disease.x. 9 Despite the fact that purified rHuEPO is available, there is no crystal or nuclear magnetic resonance (NMR) structure available. Thus it has also been difficult to definitively identify the active site of the molecule. One approach that can be successful for structure-function studies on cytokines like rHuEPO is to isolate and characterize antibodies and use them for immunoassays. For example, epitope mapping with neutralizing monoclonal antibodies (MoAbs) can reveal information about the antigen's active site(s). Antibodies can also be used to determine structure. For example, epitope mapping with MoAbs to growth hormone was used to determine a low resolution structure.''' Antibodies can also be used to determine the folded state ofproteins. Thus the effect of changes in the protein, such as by in vitro mutagenesis, on the folding of the molecule can be determined.
Several groups have isolated anti-EPO and anti-EPO peptide monoclonal and polyclonal antibodies,"-2" including neutralizing antibodies,",'~,'4,'h.'8.'y and some immunological studies have been done. Antibodies raised against EPO peptides that contain amino acid residues 99 to 126 are neutralizing which suggests that this region may include the active site." Another immunological study suggests that the carboxy terminal region contains the active site.'' In the absence of structural information it is not clear if these regions contain the entire, part of, or are simply near to the active site. In addition, the epitopes recognized by MoAbs and the effect of EPO conformation on immunoreactivity is known in only a few cases.
clonal. The 9G8A immunoassay was novel and useful because immunoreactivity increased when rHuEPO was denatured. Disruption of disulfide bonds or removal of carbohydrate increased 9G8A immunoreactivity, which suggests that these elements are important for rHuEPO structure or stability.
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We describe here the isolation and characterization of three different MoAbs that recognize nonoverlapping rHuEPO epitopes. Two of these antibodies (Dl I and F12) recognize conformation dependent epitopes. That is, rHuEPO must be properly folded for high affinity binding. In contrast, 9G8A which recognizes a linear epitope, shows an enhanced immunoreactivity to denatured rHuEPO. This property of 9G8A has allowed us to develop a novel immunoassay to detect changes in rHuEPO structure.
MATERIALS AND METHODS

Materials.
Purified monkey EPO (rmkyEPO), glycosylated rHuEPO from Chinese hamster ovary (CHO) cells, and unglycosylated rHuEPO expressed in Escherichia coli were obtained from T. Strickland and Ken Aoki (Amgen, Thousand Oaks, CA). Unglycosylated rHuEPO expressed in E coli was purified and refolded as described previously." The E coli expressed rHuEPO has assumed the proper protein fold as assessed by circular dicroism and fluorescence spectroscopy. In addition, in vitro EPO bioassays revealed an approximate twofold to threefold increase in activity relative to rHuEPO produced in C H 0 cells. Mouse EPO (MsEPO) was obtained from Boehringer Mannheim (Indianapolis, IN). Recombinant mouse EPO (rMsEPO) was produced from C H 0 cells (obtained from G. Goldwasser, University of Chicago) and was obtained from T. Strickland and K. Aoki (Amgen). Horseradish peroxidase (HRP) labeled proteins were prepared by the method of Tijssen." The EPO standard used in assays was purified rHuEP0."
To prepare denatured rHuEPO, it was treated with 5.6 mol/L GnHCI, 40 mmol/L dithiothreitol, 50 mmol/L Tris pH 8.5 for 60 minutes at room temperature (RT) then stored at 4°C and assayed directly (preparation l). A second denatured preparation was made in the same way except 0.1 v01 of I .S mol/L iodoacetic acid sodium salt was subsequently added to prevent reformation of disulfide bonds. Incubation was for 20 minutes at RT. The denatured rHuEPO solution was then extensively dialyzed against phosphate buffered saline (PBS; 10 mmol/L Na.P04 pH 6.8/150 mmol/L NaCI). The protein concentration for denatured preparation I was determined from the absorbance at 280 nm of the original rHuEPO and then was corrected for dilutions. The protein concentration of preparation 2 was determined by Bradford protein assay (BioRad, Richmond, CA).
For purified proteins, specific activities were calculated from relative activity by dividing by protein concentration calculated from the absorbance at 280nm
or Bradford protein assay. In all other cases, immunoreactivities relative to a rHuEPO standard are reported in units per milliliter (U/mL).
Anti-rHuEPO polyclonal antibodies were raised in rabbits against purified rHuEPO produced in C H 0 cells. Platelet-derived growth HybridodMoAb production. Balb c mice were immunized with rHuEPO (Amgen) using Freunds adjuvant. Hybridoma lines were made using the polyethylene glycol (PEG) procedure as de~cribed.'~ Cell lines were cloned from single cells following limiting dilution.
Ascites fluid was obtained from Balb CX CD-l hybrid mice.25 MoAbs were purified by ammonium sulfate precipitation (F12), with protein A (D1 1, 9G8A) , or by hydroxyapatite column chromatography (D11) as d e s~r i b e d .~~~~' Purified MoAbs were aliquoted and stored at less than 10°C.
Western immunoblotting. Samples were subjected to sodium dodecyl sulfate-polyarcrylamide gel electrophoresis (SDS-PAGE) according to standard methods. Proteins were transferred to 0.2 pm nitrocellulose (Schleicher and Schuell, Keene, NH) using a transblot apparatus (Idea Scientific, Corvallis, OR). The blots were blocked for 1 hour with PBS buffer containing 10% goat serum then antibody in PBS buffer with 5% goat serum and allowed to incubate overnight. The blot was washed with PBS and then processed with a Vectastain antimouse IgG kit as described by the manufacturer (Vector Laboratories, Burlingame, CA) and developed with 4-CN (GIBCO-BRL, Grand Island, NY).
Radioimmunoassay (RIA). RIA-P uses an anti-rHuEPO polyclonal antibody raised in rabbits and has been described prev i o u~l y .~~~*~ RIA-NIZ uses a rabbit polyclonal antibody raised against a synthetic peptide (amino acids I to 20 of human EPO).
For RIA assays with 9G8A. purified rabbit anti-rHuEPO polyclonal antibody (862) were coated on polystyrene wells at RT for 2 hours in 0.05 moln carbonatelbicarbonate pH 9.2 buffer. The wells were then blocked at RT for 30 minutes with 5% bovine serum albumin (BSA) in PBS. Samples or standards (50 uL) in PBS with 1% BSA were incubated in the wells for 3 hours at RT. Excess purified 9G8A antibody (50 uL of 30 pglmL) was then added and incubated overnight at RT. The next day the wells were washed 3 times with KPL wash solution (Kirkegard and Perry Labs Inc, Gaithersburg, MD), then incubated at RT for 45 minutes with IZ5I-rabbit antimouse IgG (New England Nuclear, Boston, MA) diluted in normal horse serum (200,000 cpm per well). The wells were then washed 5 times with KPL wash solution and counted.
Enzyme-linked immunosorbent assay (ELISA). To prepare rHuEPO coated wells, 150 ng of rHuEPO in 50 mmoVL Tris, 150 mmol/L NaCI, 10 mmol/L EDTA pH 7.4 was coated onto Dynatech (Chantilly, VA) round bottom microtiter wells during an overnight incubation. The wells were then blocked overnight to prevent nonspecific binding. The blocked plates were dried for up to 72 hours and stored at 2 to 8°C until use.
To prepare anti-Fc wells, a 2 pg/mL solution of goat-antimouse (Fc) antibody (Kirkegard and Perry Labs Inc) was incubated overnight in round bottom microtiter wells. 0.1% BSA was used as an overnight block solution. The wells were then dried at RT and stored at 2 to 8°C until use.
Microtiter wells coated with the respective MoAb were made using the methods outlined by Tijssen." Coated wells were stored at 2 to 8°C until use.
Several methods were used to determine the immunoreactivity of MoAb solutions or to determine rHuEPO concentrations. All reactions were done in microtiter plates with either TMB or OPD (Kirkegard and Perry Labs Inc) as substrates. Reactions with TMB were stopped with 0.5 molL HZS04 whereas OPD reactions were stopped with 2.5 mol/L HzS04. The plates were read at 450 nm/630 nm for TMB and at 490 n d 6 3 0 nm for OPD.
( I ) Anti-EPO antibody containing samples were diluted 1: 1 in buffer and added to rHuEPO coated wells and incubated 2 hours at 37°C. The plate contents were removed and rabbit antimouse HRP conjugated secondary antibody was added and incubated at 37°C for 30 minutes. The plates were then washed 5 times with TEN buffer (50 mmoVL Tris pH 7.4, I O mmol/L EDTA, 150 mmolL NaCl) and then developed. (2) Anti-EPO antibody containing samples were incubated for 2 hours at RT in antimouse Fc wells. After removal of the solution, HRP conjugated rHuEPO was added to each well and allowed to incubate at 37°C for 2 hours. The wells were then washed 4 times with TEN containing 0.01% Triton X-100 (Bio-Rad, Richmond, CA) and then developed. (3) Anti-EPO antibody containing samples were incubated in the antimouse (Fc) wells for 2 hours at RT. After removal of the solution, EPO containing solutions were added and allowed to incubate at RT for 2 hours. The solution was removed and 50 pL HRP conjugated anti-rHuEPO rabbit antibody was added and incubated at 37°C for 2 hours. The wells were then washed 4 times with 0.1% Triton X-100 in TEN and developed. (4) EPO containing samples were added to antibody coated wells and incubated at RT for 2 hours. The solution was removed and HRP conjugated anti-rHuEPO polyclonal antibody, raised in either rabbits (R) or goats (G), was then added to each well and incubated at 37°C for 2 hours. The wells were then washed 4 times with 0.1% Triton X-l00 in TEN and developed.
Antibody competition assays.
Microtiter wells were coated for 2 hours with MoAbs 9G8A, F12, or D1 1 in 0.05 mol/L carbonate/ bicarbonate pH 9.2 buffer. To test for competition, antibodies, and Iz5I rHuEPO (25,000 cpm in 100 pL; Amersham, Arlington Heights, IL) were added to the coated wells and incubated at RT for 3 hours. The wells were then washed 5 times with KPL wash solution and counted in a gamma counter.
In vitro bioassays. Erythroid colony forming assays were performed as described by Iscove et all" with the following modifications. The mononucleated cells from human bone marrow cells were partially purified on a ficoll-hypaque cushion and washed in Iscove medium before plating on tissue culture dishes to remove adherent cells. The culture medium contained 0.9% methylcellulose instead of OX%, and did not include any BSA. The erythroid colonies were scored after 7 to 10 days of culture.
In vitro bioactivity was also determined by measuring thymidine uptake in a factor-dependent cell line, 32D3'.32 that had been made dependent on EPO for growth by introduction of a murine EPO receptor gene (32D + EPOR3'). Assays were performed as deusing rHuEPO as standard with the following modifications. 32D cells were factor-starved for 3 to 5 hours in assay medium lacking EPO. Test samples or EPO standard (rHuEPO) were added to wells in a 96-well microtiter plate. Fifty microliters of starved cells was then added (15,000 cellslwell) and plates were incubated in a humidified incubator at 37°C and 6% CO2. After I8 to 24 hours, 50 uL methyl-3H-Thymidine (1 mCi/mL; 20 Ci/mmol) diluted 1: 100 in assay medium was added. Plates were incubated for an additional 4 hours at 37°C and 6%
CO2. Labeled cells were procured onto glass fiber filtermats using a PHD cell harvester (Cambridge Technology Inc, Watertown, MA) and deionized water as a washing solution followed by 2-Propanol. The filters were then dried and counted.
EPO neutralization assays. To determine whether antibodies would neutralize rHuEPO bioactivity, rHuEPO standard was incubated overnight with various amounts of antibodies in PBS buffer at RT. The amount of rHuEPO standard was 300 mUnits. This amount was chosen because 300 munits gave a response that was in the middle of the standard curve. The next day the samples were assayed with the erythroid colony formation in vitro bioassay as previously described above.
Construction of rHuEP0 variants and transfection of COS-I cells.
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From All rHuEPO variants were constructed by in vitro mutagenesis and supernatants containing these variants were recovered from transfected COS-l cells as described in the accompanying paper.94
RESULTS
Isolation of MoAbs and initial characterization. Two separate immunizations of mice with the same lot of rHuEPO ELLIOTT ET AL
were done and hybridomas were made. To screen the monoclonals for rHuEPO reactivity, supematants from 1,300 growth positive wells were screened using anti-Fc wells (experiment one) and supematants from 1,900 wells were screened with rHuEPO coated wells (experiment two). Twenty clones were chosen for ascites production from the results of experiment 1 and 1 clone was chosen from experiment 2. From these clones three different MoAbs were chosen for additional study. Monoclonals F1 2 and D1 I were recovered from experiment I and 9G8A was recovered from experiment 2.
Antibody cornpetition experiments. MoAbs F12. D1 I , and 9G8A were tested for their ability to compete with each other for rHuEPO binding as described in Materials and Methods. We found that all three antibodies would bind rHuEPO in this format. However, the amount of rHuEPO bound by 9G8A was significantly less than by Dl I or F12 (40-fold difference). As expected, each of the monoclonals competed with themselves (Fig 1) . However, rHuEPO binding by immobilized 9G8A was not inhibited by D1 I or F12. This indicates that 9G8A binds to a different site on rHuEPO than either Dl 1 or F12. In a similar manner rHuEPO binding by immobilized D1 1 was not inhibited by 9G8A and F12. This indicates that D1 1 binds to a different site on rHuEPO than either 9G8A or F12. F12 binding to rHuEPO was inhibited slightly by D 1 1 and 9G8A. However, the binding could not be completely inhibited and the inhibition was modest compared to inhibition of F12 by itself. These results suggest that the weak inhibition of EPO binding to F 12 by D 1 l and 9G8A is because of an indirect mechanism. This suggests that the three antibodies recognize separate nonoverlapping epitopes. Neutralization of rHuEP0 by MoAbs. To determine whether any of the three rHuEPO MoAbs could neutralize rHuEPO activity, rHuEPO was incubated overnight with varying amounts of antibody then in vitro bioactivity (erythroid colony forming assay) was determined as described in Materials and Methods. Two control antibodies were also tested, an anti-rHuEPO rabbit polyclonal antibody (862) that had been previously identified as having EPO neutralizing activity and a MoAb directed against human PDGF. The latter antibody would not be expected to neutralize rHuEPO activity. As expected, the polyclonal antibody (862) was very effective at neutralizing rHuEP0 activity and the anti-PDGF MoAb had no effect (Fig 2) , even at a 6,000-fold excess (10 pg MoAb/300 mUnit rHuEPO). Recovery of anti-EPO antibody in the 862 antiserum by EPO affinity purification was about 0.1 pg antibody per mL. Using this value as an estimate of the anti-EPO antibody concentration in 862 serum, we calculate that 10 ng would neutralize 300 mUnit of rHuEPO (sixfold excess). The ability of F12, D11, and 9G8A to neutralize 300 mUnit of rHuEPO was also tested. F12 and 9G8A had no effect on rHuEPO activity even at a excess of antibody of approximately 6,000-fold (Fig 2) . Dl 1 on the other hand did neutralize activity. Approximately 400 ng of antibody was required for 80% inhibition (250-fold excess). However, an effect could be observed at antibody doses as low as 20ng (15-fold excess). Thus, Dl 1 appears to neutralize rHuEPO activity but requires approximately 40-fold more antibody that the 862 polyclonal antibody.
Development of immunoassays. Initial tests indicated that rHuEPO could be captured by D11 and F12 when the antibodies were immobilized on microtiter plates. Therefore ELISAs were developed for F12 and D l 1 that involved initial capture of rHuEPO by the monoclonals followed by a second incubation with HRP conjugated anti-rHuEPO polyclonal signal antibodies. Two different secondary signal polyclonals were tested including goat and rabbit derived polyclonal antibodies. The assays with EIA/F12-R (rabbit), and EIND1 l-R (rabbit) gave the same results as that of the previously described RIA-P23,,28 for purified rHuEPO ( Table  1 ). The same results were obtained for conditioned medium from rHuEPO transfected COS-l cells (Table 2 ). Table 2 also shows that Dl 1 and F12 ELISA assays give the same results when either goat or rabbit secondary antibodies were used. Thus any of the combinations of monoclonals and secondary antibodies described in this report can be used to determine rHuEPO concentration.
Immunoassays using the 9G8A antibody required a different format from Dl 1 and F12 ELISA immunoassays. 9G8A attached to microtiter plates bound rHuEPO poorly (Fig 1) .
To circumvent this problem a sandwich RIA was developed that involved initial capture of rHuEPO in solution by a rabbit polyclonal antibody (862) attached to a microtiter plate then a second incubation with 9G8A followed by a third incubation with Iz5I labeled goat antimouse antibodies. The amount of ' ' ' 1 bound was found to be proportional to the amount of rHuEPO in solution.
Analysis of antibody binding by Western blots. One method to distinguish between conformational and linear epitopes is to see if the antibodies recognize denatured rHuEPO in a Western blot format. In this method, antibodies that recognize linear epitopes would be expected to recognize denatured rHuEPO and antibodies that recognize conformational epitopes would not. Therefore, we performed Western blots using two different amounts of rHuEPO that had been denatured by boiling in SDS and 2-mercaptoethanol. Initial experiments with 1 ug D1 1 or F12 gave no signal to rHuEPO. Therefore an experiment was performed using 10 ug Dl 1 or F12. As shown in Fig 3, F12 gave no signal in Western immunoblots even with 10 ug antibody. D1 1 gave a weak signal with 10 ug antibody that increased with increased amount of rHuEPO. However, 9G8A gave a strong signal with IO-fold less antibody (1 ug) than that used for F1 2 or D1 1. It is unlikely that the differences in immunoreactivity in Western blots between MoAbs F12 and D1 1 were because of different affinities for the antigen because Dl 1 was as sensitive as F12 in ELISA assays when similar amounts of antibody were used (see Fig l) . It is instead likely that F12 recognizes a conformation dependent epitope and D1 1 recognizes primarily folded rHuEPO but retains weak immunoreactivity to denatured rHuEPO.
Imrnunoreactivihl qf the antibodies to denatured rHuEPO in RIA and ELISA. To examine the immunoreactivity of the antibodies in more detail, purified rHuEPO was denatured with dithiothreitol in the presence of GnHCl and assayed directly. In this case we found that about one third of the biological activity was recovered when the sample was diluted for assay. This indicated that some of the rHuEPO had refolded into an active conformation. However, when reformation of disulfide bonds was prevented by subsequent treatment with iodoacetate rHuEPO, the biological activity was undetectable (<2 U/mg). Thus blocking disulfide bond formation prevented reformation into an active conformation.
The immunoreactivity of the denatured-iodoacetate treated rHuEPO was assessed (Table l) . F12 immunoreactivity determined by EIA/F 12-R was reduced approximately 3,000-fold relative to rHuEPO (Table l ) . Immunoreactivity determined with Dl l-R was reduced IS-fold. RIA-P also showed reduced immunoreactivity to denatured rHuEPO (250-fold). These results support the proposal that F12 and D1 I and the polyclonal antibody used in RIA-P recognize primarily folded rHuEPO and that F12 immunoreactivity is more dependent on proper rHuEPO conformation than D1 1.
We have observed that 9G8A immunoreactivity increased when rHuEPO containing samples had been frozen and thawed. This suggested that unfolding of rHuEPO increased 9G8A antibody binding. To test this possibility, the denatured and iodoacetate treated rHuEPO was assayed using RIA-9GSA. We found a 65-fold increase in 9G8A immunoreactivity with this sample as compared to untreated rHuEPO ( Table l ) . The denatured EPO sample that had not been iodoacetate treated showed a 30-to 40-fold increase in immunoreactivity as well (data not shown). This result along with the observations that 9G8A works well in Western blots and that 9G8A binds correctly folded rHuEPO in solution poorly suggests that 9G8A recognizes a linear epitope and that the epitope is either buried and exposed on denaturation or in a different conformation in folded versus denatured rHuEPO.
RIA-N uses an antibody raised to a synthetic human EPO peptide. amino acids 1 to 20. Many antipeptide antibodies are tolerant to changes in protein conformation. To test this For personal use only. on October 3, 2017. by guest www.bloodjournal.org From possibility the denatured rHuEPO sample was assayed with RIA-N. In this case the antibody reacted with the denatured rHuEPO sample. However, the slope of the linear range of the curve was slightly different from that of the rHuEPO standard. We estimated the relative immunoreactivities of rHuEPO and denatured rHuEPO measured by RIA-N by calculating the midpoint of the dose response curves. The midpoint for the denatured sample was 69% that of the rHuEPO standard. We used the standard curve to estimate the denatured rHuEPO concentration using points at the top and bottom of the linear range of curves from three different experiments. The highest value obtained was 255,000 U/ mg and the lowest was 70,000 U/mg. This range compares favorably with the specific immunoreactivity to rHuEPO (204,000 U/mg, Table 1 ). These results suggest that the immunoreactivities measured by RIA-N are similar but there are some differences in how the antibodies contact rHuEPO versus denatured rHuEPO.
Effect of disruption of disulfide bonds on immunoreactivity. Recombinant human EPO contains two disulfide bonds that join Cys7 to Cys16' and Cys29 to Cys33. 35 To determine the effect of disruption of these disulfide bonds on folding and activity, Cys to Ser mutations were introduced into rHuEPO and the variants were expressed in COS-l cells. The concentration of each rHuEPO variant in the supernatants was determined by RIA-N and other immunoassays. There was a 20-to 30-fold increase in measurements by RIA-9G8A relative to RIA-N when either disulfide bond was disrupted. These Cys to Ser rHuEPO variants were also not detected well by RIA-P, EIAD11-R, or EIA/F12-R as compared to RIA-N. Unlike EIAD1 l-R, immunoreactivity measured by EIAID11-G appeared to be less affected by the mutations. Estimates of the concentrations of Cys7/Ser rHuEPO and Cys"/Ser rHuEPO matched closely the values obtained by RIA-N ( Table 2 ). This suggests that goat and rabbit secondary antibodies used in immunoassays differ in their immunoreactivities to rHuEPO variants with disrupted disulfide bonds. All the immunoassays had similar results with natural sequence rHuEPO. These results suggest that the conformation of rHuEPO is altered when either disulfide bond is disrupted.
EIAID1 l-R immunoassays revealed additional information about the effect of mutations in the disulfide bonds on folding. Dl l-R immunoreactivity was reduced approximately 30-fold (relative to RIA-N) for the Cys7/Ser mutation, at least 20-fold for Cys16'/Ser mutation but only 2.5 fold for the C y~~~/ S e r mutation. Neither Cys7 nor Cys33 appear to be part of the D11 e~i t o p e .~~ RIA-P results were qualitatively similar to that of E I m 1 l-R. That is, the Cys7/Ser mutation had a greater effect on this immunoassay than did the Ser mutation. These results suggest that disruption of either disulfide bond in rHuEPO reduced the immunoreactivity measured by conformation sensitive antibodies, presumably because of a change in tertiary structure, and that the Cys7-Cys16' disulfide bond is more important for structure than the C~s *~-C y s~~ bond. We wished to determine what role the disulfide bonds play in in vitro biological activity. The supernatants containing rHuEPO and the rHuEPO variants were therefore assayed for their ability to stimulate thymidine uptake in the factor dependent cell line 32D+EPOR. The results are shown in Table 2 . RHuEPO expressed in COS cells had an in vitro biological activity that was comparable to the concentrations determined by RIA and EIA immunoassays. This suggests that the rHuEPO made under these conditions is fully active. In contrast there was no biological activity detected for either the Cys7/Ser or Cys'6'/Ser variants. The biological activity relative to RIA-N immunoassay was reduced over 100-fold for CysI6'/Ser and over 1,000-fold for Cys7/Ser variants. Unlike variants with mutations in the C y~~-C y s '~' disulfide bond, there was biological activity detected for a C y~~~/ S e r rHuEP0 variant. The in vitro activity was reduced approximately six fold (relative to RIA-N and EIA/D11-G). However, the biological activity matched closely the EPO concentration determined by RIA-P, 5 U/mL versus 4 U/mL. These results suggests that both disulfide bonds are important for in vitro biological activity but the C y~~~-C y s~~ disulfide bond is less important and that RIA-P measurements may underestimate the true concentrations for these rHuEPO variants.
Immunoreactivity of antibodies to unglycosylated rHuEP0. Human EPO contains 3 N-linked and 1 0-linked carbohydrate chains. To see if the carbohydrate affected antibody binding, rHuEPO was expressed in E coli to produce material lacking carbohydrate. The rHuEPO was purified and refolded into an active conformation as evidenced by in vitro bioassays and circular dicroism." Both EIA/F12 and RIA-P gave values in immunoassay that compared favorably with each other with unglycosylated rHuEPO (Table 1 ). The specific immunoreactivities of unglycosylated rHuEPO measured by EIA/F12 and RIA-P were slightly higher than that of glycosylated rHuEPO. This result indicates that carbohydrate is not required for RIA-P and EIA/F 12 immunoreactivity and may slightly inhibit immunoreactivity. Immunoreactivity measured by RIA-N appeared to be the same for both gylcosylated and unglycosylated rHuEPO. D l 1 immunoreactivity appeared to be reduced to unglycosylated rHuEPO. Apparent immunoreactivity with 9G8A was approximately 40-fold higher for unglycosylated rHuEPO than for glycosylated rHuEPO. A similar result was found for rHuEPO treated with N-glycanase to remove N-linked carbohydrate (data not shown). Therefore, either carbohydrate 9G8A binding, unglycosylated rHuEPO is less stable resulting in changes in folding that affect D11 and 9G8A immunoreactivity, or it has a more exposed 9G8A epitope.
To examine the role of carbohydrate on immunoreactivity in more detail, sialic acid on glycosylated rHuEPO was removed by neuraminidase treatment to see if sialic acid affected immunoreactivity. All the antibodies appeared to react similarly to asialo rHuEPO except 9G8A whose immunoreactivity was increased two fold. We have found that the immunoreactivity measured by RIA-9G8A to asialo rHuEPO changed with age of the sample. Fresh samples had much lower immunoreactivity than samples that had been frozen and thawed several times.
Antibody immunoreactivity of nonhuman EPO. Examination of immunoreactivity to molecules derived from different species can provide information about antibody epitopes. In
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From addition, we wished to determine which immunoassays could be used to measure EPO titers in monkeys and mice. Therefore, we examined the immunoreactivity of the 3 MoAbs and 2 polyclonal antibodies to monkey and mouse EPO. Monkey EPO differs from human EPO at 1436 and mouse EPO at 31'7.38 of the 165 positions found in rHuEPO. In addition the amino terminus in monkey EPO is extended by 3 amino acids relative to human EP0.3h It has been shown previously that RIA-P provides an accurate measure of monkey EPO concentration'' and that RIA-N does not because of differences in the amino terminus.'' Immunoreactivity measured by EINDI l-R and RIA-9G8A of monkey EPO compared favorably to that measured by RIA-P. This suggests that the amino acid differences between monkey and human EPO are not at positions recognized by 9G8A, D1 I or the antibody used in RIA-P.
F12 immunoreactivity to monkey EPO was reduced over 10,000-fold (EINF12-R. Table 1 ). This indicates that the amino acid differences between human EPO and monkey EPO are part of or affect the F12 epitope. Immunoreactivities measured by RIA-P. EIA/FI 2-R, EIA/DI l-R, and RIA-9G8A relative to RIA-N were all reduced when rMsEPO was assayed ( 3 , 8,000, 200. and 500-fold, respectively). Similar results were obtained with mouse EPO obtained from Boehringer Mannheim (data not shown). These results suggest that the amino acid differences in mouse EPO may include antibody epitopes for all the monoclonals.
Another possibility is that rMsEPO is folded differently than is rHuEPO and thus the epitopes are altered
DISCUSSION
Three different monoclonals and two polyclonals raised against rHuEPO were isolated and characterized. Immunoassays with each have been developed and all can be used to determine concentrations of rHuEPO. Competition experiments indicate that the three MoAbs recognize nonoverlapping epitopes. In vitro EPO bioassays indicate that D1 1 is neutralizing whereas F12 and 9G8A are not. This suggests that the D1 1 epitope is part of, or overlaps, the receptor binding site and F12 and 9G8A do not. However, the results with 9G8A must be viewed with caution. The affinity of 9G8A for rHuEPO in solution is low and therefore the antibody may not effectively block receptor binding and be unable to neutralize. The antibodies and immunoassays described here can be used to determine whether EPO conformation has been altered. The antibody used in RIA-N appears to be relatively tolerant to changes in conformation as evidenced by its ability to react with denatured rHuEPO. In contrast, the monoclonals D l 1 and F12 and the rabbit anti-rHuEPO polyclonal antibody used in RIA-P appear to recognize conformational epitopes. Thus, their immunoreactivities are reduced for denatured rHuEPO. F12 is much more sensitive to changes in rHuEPO conformation than D I 1. In addition we describe a novel immunoassay based on the MoAb 9G8A. Immunoreactivity with this antibody increases when the protein is denatured.
The utility of using such conformation sensitive immunoassays is illustrated in experiments used to establish the role of rHuEPO disulfide bonds on structure and activity. We have found that Cys3' to Ser, Cys7 to Ser and Cys'" to Ser mutations all result in increases in immunoreactivity with 9G8A and decreases in immunoreactivity measured by RIA-P, EIAIF12, and EIAlDI 1 -R relative to RIA-N. A similar result was found for a Cys" to Pro mutation.'3 Thus these mutations appear disrupt rHuEPO structure and presumably affect immunoreactivity of RIA-P and F12 indirectly. These mutations also affect in vitro biological activity. Mutations that disrupt the Cys7-Cyslhl disulfide bond appear to alter rHuEPO structure and in vitro biological activity to a greater degree than mutations that disrupt the Cy~'~--Cys~' disulfide bond. This is evidenced by the greater effect of the mutations on D1 1, RIA-P immunoreactivity, and in vitro bioactivity. Therefore, both of the disulfide bonds play an essential role in maintaining the protein in the proper folded state which in turn is required for full biological activity.
The importance of the Cy~'-Cys'~' bond in biological activity is in agreement with that of Boissel et al.'" However there are apparent differences on the role of the Cy~'"-Cys'~ disulfide bond. It was reported that mutation of either Cys'", Cys", or both to Tyr resulted in normal in vitro biological activity.'" Several explanations for the difference are apparent. One possibility is that Tyr substitutions are more favorable substitutions for rHuEPO conformation than the Ser or Pro substitutions we introduced. The EPO variants were not purified in either study and the quantitation of EPO concentration depended on immunoassay. Thus another possibility is that the different results are because of disparities in the method used to quantitate EPO concentration. We have prepared a similar rabbit polyclonal antibody (used in RIA-P) to that used by Boissel et al, and found that the EPO concentration determined by RIA-P matches the in vitro activity. In our calculation of specific activity we used the RIA-N and EIA/DI 1 -G immunoassays to estimate rHuEPO concentration. These immunoassays give higher estimates of rHuEPO concentration and thus reduced specific activity estimates.
The importance of carbohydrate for rHuEPO structure/ stability was suggested by immunoassay. 9G8A immunoreactivity increased when carbohydrate was removed. This result suggests several possibilities. The epitope recognized by 9G8A may be masked by the carbohydrate. This appears unlikely because removal of any single N-linked oligosaccharide chain by in vitro mutagenesis only modestly affects 9GSA immunoreactivity,"' and removal of the 0-linked site has no effect, but 9G8A immunoreactivity increases dramatically when all 3 N-linked sites are removed. Thus, the effect on 9G8A immunoreactivity is elicited only with completely unglycosylated rHuEPO. A second possibility is that removal of carbohydrate results in a change in rHuEPO structure that exposes the 9G8A epitope. However. a change in structure of rHuEPO when carbohydrate was removed could not be detected by circular dicroism." Therefore, the change in rHuEPO structure when carbohydrate is removed would have to be subtle and affect structure to a degree detectable by antibody binding and not by circular dicroism. A third possibility is that unglycosylated rHuEPO is unstable and quickly unfolds. It F1 2 and partially by D l 1 and 9G8A . Fine-structure epitope mapping indicates that F12 recognizes residues at positions 31 to 33, 86 to 88, and 138.33 Mouse EPO differs from rHuEPO at positions 32 to 34 and 88 and monkey EPO differs at position 32 and 88. Thus these differences can account for the reduced F12 immunoreactivity. 9G8A recognizes a linear epitope near the N -t e r m i n~s . ~~ In the N-terminal region at the 9G8A binding site, mouse, rHuEPO, and monkey EPO differ only at amino acid position 16. Mouse EPO has a Ile at this position and rHuEPO and monkey EPO have a Leu. Thus, the difference in 9G8A immunoreactivity can be accounted for by the differences at position 16. Epitope mapping data suggests that D l 1 recognizes amino acids 64, 67, 72, 75, 100, 103, 106, and 1 10." However, mouse and rHuEPO have identical residues at all of these positions. It is possible that other, unidentified, residues are part of the D1 1 epitope and those differ in mouse and rHuEPO. Another possibility is that the reduced immunoreactivity is caused by conformational differences in the D l 1 epitope between mouse and rHuEPO.
